Molecular Profiling Identifies CD49d and CD79b as Predictive Markers for Acquired Acalabrutinib Resistance in Patients With Chronic Lymphocytic Leukemia.
Bibikova E, Parsa S, Floren M, Law B, Clevenger T, Cheung J, De Jesus G, Burke K, Gulrajani M, Yamaguchi K, Do P, Dougherty B, Whitston D, Brock G, Munugalavadla V, Frigault MM, Hartmann TN, Byrd JC, Furman RR, Brown JR, Covey T, Mortlock A.
Bibikova E, et al. Among authors: whitston d.
Hematol Oncol. 2025 Jan;43(1):e70008. doi: 10.1002/hon.70008.
Hematol Oncol. 2025.
PMID: 39716442
Clinical Trial.